Mitochondrially targeted α-tocopheryl succinate is antiangiogenic: Potential benefit against tumor angiogenesis but caution against wound healing

Antioxidants and Redox Signaling

Volumn 15, Issue 12, 2011, Pages 2923-2935

  Rohlena, Jakub ^a   Dong, Lan Feng ^b   Kluckova, Katarina ^a   Zobalova, Renata ^a,b   Goodwin, Jacob ^b   Tilly, David ^b   Stursa, Jan ^b,c   Pecinova, Alena ^d   Philimonenko, Anatoly ^e   Hozak, Pavel ^e   Banerjee, Jaideep ^f   Ledvina, Miroslav ^c   Sen, Chandan K ^f   Houstek, Josef ^d   Coster, Mark J ^b   Neuzil, Jiri ^a,b  

^a INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

^b GRIFFITH UNIVERSITY   (Australia)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^d INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^e INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; ANGIOGENESIS INHIBITOR; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR; WOUND HEALING;

ALPHA-TOCOPHEROL; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; WOUND HEALING;

MUS MUSCULUS;

EID: 80155213980     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4192     Document Type: Article

References (47)

1. Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, Bono M, Ferrantini M, Rozera C, Truini M, Belardelli F, Santi L, and Noonan DM. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 156: 1381-1393, 2000.
2. Biswas S, Roy S, Banerjee J, Hussain SR, Khanna S, Meenakshisundaram G, Kuppusamy P, Friedman A, and Sen CK. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci U S A 107: 6976-6981, 2010.
3. Cross MJ and Claesson-Walsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22: 201-207, 2001.
4. De Pinto V, Prezioso G, Thinnes F, Link TA, and Palmieri F. Peptide-specific antibodies and proteases as probes of the transmembrane topology of the bovine heart mitochondrial porin. Biochemistry 30: 10191-10200, 1991.
5. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, and Hogg PJ. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3: 497-509, 2003.
6. Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M, Rohlena J, Rodriguez-Enriquez S, Valis K, Butcher B, Goodwin J, Brunk UT, Witting PK, Moreno-Sanchez R, Scheffler IE, Ralph SJ, and Neuzil J. Suppression of tumour growth in vivo by the mitocan a-tocopheryl succinate requires respiratory complex II. Clin Cancer Res 15: 1593-1600, 2009.
7. Dong LF, Jameson VJA, Tilly D, Cerny J, Mahdavian E, Maŕn- Hernández A, Hernández-Esquivel L, Rodŕguez-Enŕquez S, Witting PK, Stantic B, Rohlena J, Truksa J, Kluckova K, Dyason JC, Salvatore BA, Moreno-Sánchez R, Coster MJ, Ralph SJ, Smith RAJ, and Neuzil J. Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J Biol Chem 286: 3717-3728, 2011.
8. Dong LF, Jameson VJA, Tilly D, Prochazka L, Rohlena J, Valis K, Truksa J, Zobalova R, Mahdavian E, Kluckova K, Stantic M, Stursa J, Wang XF, Freeman R, Witting PK, Norberg E, Goodwin J, Salvatore BA, Novotna J, Turanek J, Ledvina M, Hozak P, Zhivotovsky B, Coster MJ, Ralph SJ, Smith RAJ, and Neuzil J. Mitochondrial targeting of a-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm of efficient anti-cancer therapy. Free Radic Biol Med 50: 1546-1555, 2011.
9. Dong LF, Low P, Dyason J, Wang XF, Prochazka L, Witting PK, Freeman R, Swettenham E, Valis K, Liu J, Zobalova R, Turanek J, Spitz DR, Domann FE, Scheffler IE, Ralph SJ, and Neuzil J. A-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 27: 4324-4335, 2008.
10. Dong LF, Swettenham E, Eliasson J, Wang XF, Gold M, Medunic Y, Stantic M, Low P, Prochazka L, Witting PK, Turanek J, Akporiaye ET, Ralph SJ, and Neuzil J. Vitamin E analogs inhibit angiogenesis by selective apoptosis induction in proliferating endothelial cells: The role of oxidative stress. Cancer Res 67: 11906-11913, 2007.
11. Edgell CJ, McDonald CC, and Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A 80: 3734-3737, 1983.
12. Fantin VR and Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 5: 4787-4797, 2006.
13. Folkman J. Angiogenesis. Annu Rev Med 57: 1-18, 2006.
14. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286, 2007.
15. Folkman J and Shing Y. Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
16. Fulda S, Galluzzi L, and Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464, 2010.
17. Gane EJ, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, and Murphy MP. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 30: 1019-1026, 2010.
18. Gogvadze V, Orrenius S, and Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18: 165-173, 2008.
19. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, and Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89: 1078-1082, 1992.
20. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ. Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
21. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, and Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 276: 4588-4596, 2001.
22. Malafa MP, Fokum FD, Andoh J, Neitzel LT, Bandyopadhyay S, Zhan R, Iiizumi M, Furuta E, Horvath E, and Watabe K. Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis. Int J Cancer 118: 2441-2447, 2006.
23. Malafa MP, Fokum FD, Mowlavi A, Abusief M, and King M. Vitamin E inhibits melanoma growth in mice. Surgery 131: 85-91, 2002.
24. Moreno-Sánchez R, Rodŕguez-Enŕquez S, Maŕn-Hernández A, and Saavedra E. Energy metabolism in tumor cells. FEBS J 274: 1393-1418, 2007.
25. Murphy MP and Smith R. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629-656, 2007.
26. Neuzil J. Vitamin E succinate and cancer treatment: a vitamin E prototype for selective anti-tumour activity. Br J Cancer 89: 1822-1826, 2003.
27. Neuzil J, Dong LF, Ramanathapuram L, Hahn T, Chladova M, Wang XF, Zobalova R, Prochazka L, Gold M, Freeman RE, Turanek J, Akporiaye ET, Dyason J, and Ralph SJ. Vitamin E analogues: a novel group of mitocans, anti-cancer agents that act by targeting mitochondria. Mol Aspects Med 28: 607-645, 2007.
28. Neuzil J, Schröder A, von Hundelshausen P, Zernecke A, Weber T, Gellert N, and Weber C. Inhibition of inflammatory endothelial responses by a pathway involving caspase activation and p65 cleavage. Biochemistry 40: 4686-4692, 2001.
29. Neuzil J, Swettenham E, Wang XF, Dong LF, and Stapelberg M. A-Tocopheryl succinate inhibits angiogenesis by disrupting paracrine FGF2 signalling. FEBS Lett 581: 5611-5615, 2007.
30. Neuzil J, Tomasetti M, Zhao Y, Dong LF, Birringer M, Wang XF, Low P, Wu K, Salvatore BA, and Ralph SJ. Vitamin E analogs, a novel group of 'mitocans', as anti-cancer agents: The importance of being redox-silent. Mol Pharmacol 71: 1185-1199, 2007.
31. Neuzil J, Wang XF, Dong LF, Low P, and Ralph SJ. Molecular mechanism of 'mitocan'-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. FEBS Lett 580: 5125-5129, 2006.
32. Neuzil J, Weber T, Gellert N, and Weber C. Selective cancer cell killing by a-tocopheryl succinate. Br J Cancer 84: 87-89, 2001.
33. Park D and Dilda P. Mitochondria as targets in angiogenesis inhibition. Mol Asp Med 31: 113-131, 2010.
34. Prochazka L, Dong LF, Valis K, Freeman R, Ralph SJ, Turanek J, and Neuzil J. A-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channel. Apoptosis 15: 782-794, 2010.
35. Rafii S, Lyden D, Benezra R, Hattori K, and Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2: 826-835, 2002.
36. Roy S, Biswas S, Khanna S, Gordillo G, Bergdall V, Green J, Marsh CB, Gould LJ, and Sen CK. Characterization of a preclinical model of chronic ischemic wound. Physiol Genomics 37: 211-224, 2009.
37. Schägger H and von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166: 368-379, 1987.
38. Singh M, Brooks GC, and Srere PA. Subunit structure and chemical characteristics of pig heart citrate synthase. J Biol Chem 245: 4636-4640, 1970.
39. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, and Taylor KM. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 25: 1670-1674, 2010.
40. Stapelberg M, Gellert N, Swettenham E, Tomasetti M, Witting PK, Procopio A, and Neuzil J. A-Tocopheryl succinate inhibits malignant mesothelioma by disrupting the FGF autocrine loop: the role of oxidative stress. J Biol Chem 280: 25369-25376, 2005.
41. Sun F, Huo X, Zhai Y, Wang A, Xu J, Su D, Bartlam M, and Rao Z. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell 121: 1043-1057, 2005.
42. Tomasetti M, Gellert N, Procopio A, and Neuzil J. A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a prototype of a future drug against a fatal neoplastic disease? Int J Cancer 109: 641-642, 2004.
43. Trachootham D, Alexandre J, and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
44. Valis K, Prochazka L, Boura E, Chladova M, Obsil T, Rohlena J, Truksa J, Dong LF, Ralph SJ, and Neuzil J. Hippo/ Mst1 stimulates transcription of NOXA in a FoxO1-dependent manner. Cancer Res 71: 946-954, 2011.
45. Wang XF, Birringer M, Dong LF, Veprek P, Low P, Swettenham E, Stantic M, Yuan LH, Zobalova R, Wu K, Ralph SJ, Ledvina M, and Neuzil J. A peptide adduct of vitamin E succinate targets breast cancer cells with high erbB2 expression. Cancer Res 67: 3337-3344, 2007.
46. Weber T, Dalen H, Andera L, Nègre-Salvayre A, Augé N, Sticha M, Loret A, Terman A, Witting PK, Higuchi M, Plasilova M, Zivny J, Gellert N, Weber C, and Neuzil J. Mitochondria play a central role in apoptosis induced by atocopheryl succinate, an agent with anticancer activity. Comparison with receptor-mediated pro-apoptotic signaling. Biochemistry 42: 4277-4291, 2003.
47. Weber T, Lu M, Andera L, Lahm H, Gellert N, Fariss MW, Korinek V, Sattler W, Ucker DS, Terman A, Schröder A, Erl W, Brunk U, Coffey RJ, Weber C, and Neuzil J. Vitamin E succinate is a potent novel anti-neoplastic agent with high tumor selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo2L) in vivo. Clin Cancer Res 8: 863-869, 2002.